Audicus Applauds FDA Announcement To Move Closer To Making Hearing Care More Accessible To Millions Of Americans

First Company To Offer Fully Customizable Hearing Aids Online

Audicus, the first company to offer fully customizable hearing aids online, and a leading provider of hearing aids via telehealth, responded today to the FDA’s proposed rule to establish a new category of over-the-counter (OTC) hearing aids. The proposed rule will allow for certain classes of hearing aids to be sold directly to consumers without the need for a fitting from an Audiologist, increasing accessibility to hearing care for the 37.5 million American adults with some form of hearing loss.

“Audicus pioneered the movement in making high quality hearing care more accessible and affordable nearly a decade ago,” said Patrick Freuler, Founder and CEO of Audicus. “We welcome the FDA’s proposed rule to create a class of OTC hearing aids and see it as a milestone towards greater access. This decision could only allow us to further reach those in need of hearing solutions, and deliver life-changing devices to them at a fraction of the cost of traditional channels,” he continued.

Throughout the COVID-19 pandemic, Audicus has seen the increased need to provide quality telehealth services, as well as a positive shift in seniors’ attitudes towards technology. In a survey of 330 seniors, Audicus found that 16% have used telemedicine services since the start of the pandemic, as compared to 5% before. Furthermore, 25% of seniors report now making video calls, as compared to 15% before. With this FDA proposal, Audicus recognizes that ongoing support through technology will be even more important for OTC hearing aids.

“We have helped hundreds of thousands of seniors learn about their hearing through our proprietary online hearing assessment and educational programming,” said Freuler, “and we look forward to continuing to provide expert care and support to the millions of seniors who are in need of hearing care.”

SourceAudicus

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”